NewEdge Advisors’s Seres Therapeutics MCRB Stock Holding History

NewEdge Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10	Closed	-$145	–	3889
2024 Q2	$145	Buy	+10	New	+$167	﹤0.01%	3670

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

NewEdge Advisors's MCRB Position: Q3 2024 in Review

NewEdge Advisors sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 10 shares — an estimated $145 sold.

NewEdge Advisors first reported a position in MCRB in Q2 2024 and held it in 1 quarter. The position peaked at $145 in Q2 2024. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

NewEdge Advisors reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
NewEdge Advisors sold 10 Seres Therapeutics shares in Q3 2024, an estimated $145.
NewEdge Advisors first reported a position in Seres Therapeutics in Q2 2024 and held it in 1 quarter.
NewEdge Advisors's Seres Therapeutics position peaked at $145 in Q2 2024.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.